Published in Vaccine Weekly, November 1st, 2000
In a study of the "immunogenicity of a recombinant HIV-1 envelope vaccine (rgp160) in late HIV infection," A. Demaria and colleagues, Bureau of Communicable Disease Control, Massachusetts, enrolled 142 HIV infected patients who had CD4+ T lymphocyte counts of <400/mm3, "in a dose-comparison, open-label trial with stratification by CD4+ cell count, randomization to a primary series at two dose levels, and a sub-group receiving interferon-gamma (IFN-gamma) as an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.